FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	C1039/7021	09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	**GROUP** ~~1617~~ 1633

U.S. PATENT DOCUMENTS

Exam Init	~~Ref Des~~	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
A1	✓	**5,417,972**	**05/23/95**	**Bhat et al.**	**424**	**137.1**	
*	✓	3,906,092	09/16/75	Hilleman et al.	424	89	
*	✓	5,248,670	09/28/93	Draper et al.	514	44	
A2	✓	**5,445,938**	**08/29/95**	**Hanai et al.**	**435**	**7.23**	
A3	✓	**5,491,088**	**02/13/96**	**Hellstrom et al.**	**435**	**240.24**	
*	✓	5,585,479	12/17/96	Hoke et al.	536	24.5	
*	✓	5,663,153	09/02/97	Hutcherson et al.	514	44	
*	✓	5,723,335	03/03/98	Hutcherson et al.	435	375	
A4	✓	**5,756,097**	**05/26/98**	**Landucci et al.**	**424**	**155.1**	
*	✓	5,786,189	07/28/98	Locht et al.	435	172.3	
A5	✓	**5,837,243**	**11/17/98**	**Deo et al.**	**424**	**136.1**	
*	✓	5,849,719	12/15/98	Carson et al.	514	44	

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	Translation No
*	✓	WO 91/12811	09/05/91	~~PCT~~ WO	~~A61K~~	~~31/70~~		
*	✓	0468520 A3	01/29/92	~~EPO~~ EP	~~A61K~~	~~31/70~~		
*	✓	WO 92/03456	03/05/92	~~PCT~~ WO	~~C07H~~	~~15/12~~		
*	✓	WO 92/18522	10/29/92	~~PCT~~ WO	~~C07H~~	~~21/00~~		
*	✓	WO 92/21353	12/10/92	~~PCT~~ WO	~~A61K~~	~~31/70~~		
*	✓	0302758 ~~B1~~ B1	03/16/94	~~EPO~~ EP	~~C12N~~	~~15/37~~		
*	✓	WO 94/19945	09/15/94	~~PCT~~ WO	~~A01N~~	~~43/04~~		
*	✓	WO 95/05853	03/02/95	~~Regents of the University of CA~~ WO	—	—		
*	✓	WO 95/26204	10/95	~~PCT~~ WO	~~A61K~~	~~48/00~~		
*	✓	WO 96/02555	02/01/96	~~PCT~~ WO	—	—		
*	✓	WO 96/35782	11/14/96	~~Applied Research Systems~~ WO	—	—		
*	✓	WO 97/28259	08/07/97	~~PCT~~ WO	~~C12N~~	~~15/00~~		
*		~~WO 98/18810~~ ✓	~~05/07/98~~	~~PCT~~	~~C07H~~	~~21/00~~		
*		~~WO 98/37919~~ ✓	~~09/03/98~~	~~PCT~~	~~A61K~~	~~49/00~~		
*		~~WO 98/40100~~ ✓	~~09/17/98~~	~~PCT~~	~~A61K~~	~~39/39~~		

9/27/00

413072.1

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1039/7021	SERIAL NO 09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	GROUP 1617

*		~~WO 98/52581~~	~~11/26/98~~	~~PCT~~	~~A61K~~	~~35/00~~		
*		WO 98/14210	04/09/98	~~PCT~~ WO	~~A61K~~	~~39/35~~		

OTHER ART
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

*		Adya N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. *Proc Natl Acad Sci USA* 91(12):5642-6, 7 Jun 1994.
*		Angier, N., Microbe DNA Seen as Alien By Immune System, *New York Times*, 4/11/95
*		Azad RF et al., Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-Early Region. *Antimicrobial Agents and Chemotherapy*, 37:1945-1954, September, 1993.
*		Azuma, Biochemical and Immunological Studies on Cellular Components of Tubercle Bacilli, *Kekkaku*, Vol. 69, 9:45-55, 1992.
*		Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. *J Immunol* 157(5):1840-5, 1996.
*		Bayever, E., Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial, *Antisense Res. & Dev.* (1993), 3:383-390.
*		Bennett RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. *J Clin Invest* 76(6):2182-90, 1985.
*		Berg DJ et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. *J Clin Invest* 96(5):2339-47, 1995.
C1		**Bernhard, M., et al., "Monocyte Macrophage Mediated Antibody Depedent and Independent Cell Mediated Cytotoxicity in Normals and Cancer Patients, ABSTRACT, *Proceedings of AACR and ASCO*, 22:372, c-159**
*		~~Blanchard DK et al., Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. *J Immunol* 136(3):963-70, 1986.~~
*		Blaxter et al., Genes expressed in Brugia malayi infective third stage larvae. *Molecular and Biochemical Parasitology*, 77:77-93.
*		Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. *Antisense Nucleic Acid Drug Dev* 7(5):461-71, Oct 1997.
*		Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. *J. Lab Clin Med* 128(3):329-38, Sep 1996.
*		Branda et al., Immune Stimulation by an Antisense Oligomer Complementary to the rev gene of HIV-1. *Biochemical Pharmacology*, Vol. 45, 10:2037-2043, 1993.
*		Briskin M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation. *Mol Cell Biol* 10(1):422-5, Jan 1990.
*		Chace, J. et al., Regulation of Differentiation in CD5+ and Conventional B Cells, *Clinical Immunology and Immunopathology*, (1993), 68:3:327-332.
*		Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. *J Virol* 64(1):264-77, Jan 1990.
*		Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. *J Exp Med* 186(10):1623-31, 17 Nov 1997.
C2		**Cohen, J., et al., "IL-12 Deaths: Explanation and a Puzzle", *Science*, 10:270:5238:908**

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1039/7021	SERIAL NO 09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	**GROUP** 1617

C3	✓	**Cossum, P., et al., "Pharmacokinetics of a ^{14} C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats", The Journal of Pharmacology and Experimental Therapeutics, 269:1:89-94, (1993)**
*		Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. *J Immunol* 156(12):4570-5, 15 Jun 1996.
*		Crosby et al., The Early Responses Gene FGFI-C Encodes a Zinc Finger Transcriptional Activator and is a Member of the GCGGGGGCG (GSG) Element-Binding Protein Family. *Mol. Cell. Biol.*, 2:3835-3841, 1991.
*		Crystal, Transfer of Genes to Humans: Early Lessons and Obstacles to Success. *Science*, Vol. 270, pp. 404-410, 1995.
*		~~D'Andrea A et al., Interleukin-10 (IL-10) inhibits human lymphocyte interferon-gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. *J Exp Med* 178(3):1041-8, 1993.~~
C4	✓	**Doe, B., et al., "Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is faciliated by bone marrow-derived cells", *Proc. Natl. Acad. Sci.*, 93:8578-8583, (1996)**
*		Englisch et al., Chemically Modified Oligonucleotides as Probes and Inhibitors, *Angew. Chem. Int. Ed. Engl.*, 30:613-629, 1991.
*		Erb KJ et al., Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. *J Exp Med* 187(4):561-9, 16 Feb 1998.
*		Etlinjer, Carrier sequence selection - one key to successful vaccines, *Immunology Today*, Vol. 13, 2:52-55, 1992.
*		Fox RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug. *Chemical Abstracts*, 120:15, Abstract No. 182630 (April 29, 1994).
C5		**Gately, M., et al., "Interleukin-12: A Recently Discovered Cytokine with potential for Enhancing Cell-Mediated Immune Responses to Tumors", *Cancer Investigation*, 11:4:500-506, (1993)**
*		Gura, T., Antisense Has Growing Pains. *Science* (1995), 270:575-576.
*		Hadden J et al., Immunostimulants. *TIPS*, (1993), 141:169-174.
*		Hadden J et al., Immunopharmacology, *JAMA*, (1992) 268:20:2964-2969.
*		Halpern MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. *Cell Immunol* 167(1):72-8, 1996.
C6		**Hartmann, G., et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells", *Proc. Natl. Acad. Sci.*, 96:9305-9310, (1999)**
*		Hatzfeld J., Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β1 or Rb Oligonucleotides, *J. Exp. Med.*, (1991) 174:925-929.
*		Highfield PE, Sepsis: the More, the Murkier. *Biotechnology*, 12:828, August 12, 1994.
*		Hoeffler JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. *Mol Endocrinol* 5(2):256-66, Feb 1991.
*		Iguchi-Ariga SM and Shaffner W, CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. *Genes Dev* 3(5):612-9, May 1989.
*		Iverson, P., et al., "Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against reve from Human Immunodeficiency Virus Type 1 in the Adult male Rate Following Single Injections and Continuous Infusion", *Antisense Research and Development*, (1994), 4:43-52
*		Ishikawa R et al., IFN induction and associated changes in splenic leukocyte distribution. *J Immunol* 150(9):3713-27, 1 May 1993

9/27/00

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1039/7021	SERIAL NO 09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	**GROUP** 1617

*	✓	Jakway JP et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. *J Immunol* 137(7):2225-31, 1 Oct 1986.
*	✓	Jaroszewski JW and Cohen JS, Cellular uptake of antisense oligonucleotides. *Adv Drug Delivery Rev* 6(3):235-50, 1991.
C7	✓	**Kataoka, T., et al. "Immunotherapeutid potential in Guinea-Pig Tumor Model of Deoxyribonucleic Acid From Mycobacterium Bovix BCG Complexed with Poly-L-Lysine and Carboxy-Methylcellulose", *Jpn J. Med. Sci. Biol.* 43:171-182, (1990)**
*	✓	Kimura Y et al., Binding of Oligoguanylate to Scavenger Receptors Is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN, *J. Biochem.*, Vol. 116, 5:991-994, 1994.
*	✓	Kline JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. *J Invest Med* 44(7):380A, 1996.
*	✓	Kline JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. *J Invest Med* 45(3):282A, 1997.
*	✓	Kline JN et al., CpG oligonucleotides can reverse as well as prevent Th2-mediated inflammation in a murine model of asthma. *J Invest Med* 45(7):298A, 1997.
*	✓	Klinman DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. *Proc Natl Acad Sci USA* 93(7):2879-83, 1996.
C8	✓	**Kolitz, J., et al., "The Immunotherapy of Human Cancer with Interleukin 2: Present Status and Future Directions", *Cancer Investigation*, 9:5:529-542, (1991)**
*		~~Krieg AM, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. *J Lab Clin Med* 128(2):128-33, 1996.~~
*	✓	Krieg AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. *Antisense Res Dev* 1(2):161-71, Summer 1991.
*	✓	Krieg AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. *Antisense Nucleic Acid Drug Dev* 6(2):133-9, Summer 1996.
*	✓	Krieg AM et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", *Proc. Natl. Acad. Sci.*, (1993), 90:1048-1052
*	✓	Krieg AM et al., "CpG DNA: A Pathogenic Factor in Systemic Lupus Erythematosus?", *Journal of Clinical Immunology*, (1995) 15:6:284-292
*	✓	Krieg AM et al, "Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?, *Antisense Research and Development*, (1995), 5:241
*	✓	Krieg AM et al., "Leukocyte Stimulation by Oligodeoxynucleotides", *Applied Antisense Oligonucleotide Technology*, (1998), 431-448
*	✓	Krieg AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546-9, 1995.
*	✓	Krieg AM et al, "The role of CpG dinuleotides in DNA vaccines", Trends in Microbiology, Vol. 6, pp. 23-27, Jan 1998.
*	✓	Krieg AM el al, "A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation, the Journal of Immunology, Vol. 143, 2448-2451,
*	✓	Kuramoto et al., "Oligonucleotide Sequences Required for Natural Killer Cell Activation, *Jpn. J. Cancer Res.*, 83:1128-1131, November 1992.
C9	✓	**Kuramoto et al., "In Situ Infiltration of Natural Killer-Like Cell sInduced by Intradermal Injection of the Nucleic Injection of the Nucleic Acid Fraction from BCG", *Microbiol. Immunol.*, 33:11:929-940, (1989)**

90

9/27/00

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1039/7021	SERIAL NO 09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	**GROUP** 1617

C10	✓	**Kuramoto, E., et al., "Changes of host cell infiltration into meth a fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", Int. I. Immunopharmacol. 14:5:773-782, (1992)**
C11	✓	**Lacour, J., et al., "Clinical Trials Using Polyadenylic-Polyuridylic Acid as an Adjuvant to Surgery in Treating Different Human Tumors, *J of Biological Response Modifiers*, 4:538-543, (1985)**
*	✓	Leonard et al., Conformation of Guanine 8-Oxoadenine Base Pairs in the Crystal Structure of d(CGCGAATT(08A)GCG). *Biochemistry*, 31(36):8415-8420, 1992.
*	✓	Macfarlane DE and Manzel L, Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. *J Immunol* 160(3):1122-31, Feb 1 1998.
*	✓	Mastrangelo et al. *Seminars in Oncology*. Vol. 23, 1:4-21, 1996.
C12	✓	**Mashiba, H., et al., "In Vitro Augmentation of Natural Killer Activity of Peripheral Bllod Cells From Cancer Patients by a DNA Fraction From Mycobacterium Bovis BCG", *Jpn J. Med. Sci. Biol.*, 41:197-202, (1988)**
*	✓	Matson S and Krieg AM, Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. *Antisense Res Dev* 2(4):325-30, Winter 1992.
*	✓	McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. *Antisense Res Dev* 3(4):309-22, Winter 1993.
*	✓	Messina et al., The Influence of DNA Structure on the *in vitro* Stimulation of Murine Lymphocytes by Natural and Synthetic Polynucleotide Antigens. *Cellular Immunology*, 147:148-157, 1993.
*	✓	Messina et al., Stimulation of *in vitro* Murine Lymphocyte Proliferation by Bacterial DNA. *J. Immunol.*, Vol. 147, 6:1759-1764, September 15, 1991.
*	✓	Mojcik, C., et al., "Administration of a Phosphorothioate Oligonucleotide Antisense Murine Endogenous Retroviral MCF env Causes Immune Effect in vivo in a Sequence-Specific Manner", *Clinical Immunology and Immunopathology*, (1993), 67:2:130-136
C13	✓	**Morahan, P., et al., "Comparative Analysis of Modulators of Nonspecific Resistance Against Microbial Infections", *Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance*, 313-324, (1987)**
*	✓	Mottram et al., A novel CDC2-related protein kinase from leishmania mexicana LmmCRK1 is post-translationally regulated during the life cycle. *J. Biol. Chem.* 268:28, 21044-21052 (October 1993).
*	✓	*New England BIOLABS 1988-1989 Catalog*
*	✓	Nyce JW and Metzger WJ, DNA antisense therapy for asthma in an animal model. *Nature* 385:721-725, 20 Feb 1997.
*	✓	Pisetsky, D., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", *Molecular Biology Repairs*, (1993) 18:217-221
*	✓	Pisetsky et al., Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus. *Life Science*, Vol. 54, pp. 101-107 (1994).
*	✓	Pisetsky, The Immunological Properties of DNA, *The Journal of Immunology*, pp. 421-423 (1996).
*	✓	Pisetsky, Immunological Consequences of Nucleic Acid Therapy, *Antisense Research and Development*, 5:219-225 (1995).
*	✓	Raz E et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. *Proc Natl Acad Sci USA* ~~93(10):5141-5, 14 May 1996~~ 91: 9519-9523 (1994)
C14	✓	**Reisfeld, R., et al., "Monoclonal Antibodies in Cancer Therapy", Clinics in Laboratory Medicine, 12:2:201-216, (1992)**
C15	✓	**Rosenberg, S., et al., "Immunotherapy of Cancer by Systemic Administration of Lymphoid Cells Plus Interleukin-2", *Journal of Biological Response Modifiers*, 3:501-511, (1984)-**

9/27/00 ✓

413072

9/27/00

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1039/7021	SERIAL NO 09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	**GROUP** 1617

C16		**Rosenberg, S., et al., "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukins-2 to patients with metastatic cancer", The New England Journal of Medicine, 113:23:1485-1492, (1985)**
*		Roman M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. *Nat Med* 3(8):849-54, Aug 1997.
*		Sato et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization, *Science*, Vol. 273, pp. 352-354, 1996.
*		Schnell et al., Identification and characterization of a Saccharomyces cerevisiae gene (PAR1) conferring resistance to iron chelators. *Eur. J. Biochem.*, 200:487-493.
*		~~Schwartz DA et al., Endotoxin responsiveness and grain dust-induced inflammation in the lower respiratory tract. *Am J Physiol* 267(5 Pt 1):L609-17, 1994.~~
*		Schwartz DA et al., The role of endotoxin in grain dust-induced lung disease. *Am J Respir Crit Care Med* 152(2):603-8, 1995.
*		Schwartz DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. *J Clin Invest* 100(1):68-73, 1 Jul 1997.
C17		**Shimada, S., et al., "In Vivo Augmentatio of Natural Killer Cell Activity With A Deoxyribonucleic Acid Fraction of BCG", *Jpn J. Cancer Res.*, 77:808-816, (1986)**
*		Shirakawa T et al., The inverse association between tuberculin responses and atopic disorder. *Science* 275(5296):77-9, 3 Jan 1997.
*		Sparwasser T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. *Eur J Immunol* 27(7):1671-9, Jul 1997.
*		Stein CA et al., Oligonucleotides as inhibitors of gene expression: a review. *Cancer Research*, 48:2659-2668, 1988.
C18		**Stevenson, H., et al., "The Treatment of Cancer with Activated Cytotoxic Leukocyte Subsets", *Artif Organs*, 12:2:128136, 1988**
*		Stull et al., Antigene, Ribozyme, and Aptamer Nucleic Acid Drugs: Progress and Prospects, *Pharmaceutical Res.*, Vol. 12, 4:465-483, 1995.
*		Subramanian et al., Theoretical Considerations on the "Spine of Hydration" in the Minor Groove of d(CGCGAATTCGCG) d(GCGCTTAAGCGC): Monte Carlo Computer Simulation. *Proc. Nat'l. Acad. Sci. USA*, 85:1836-1840, 1988.
*		Tanaka T et al., An antisense Oligonucleotide complementary to a sequence in IG2b increases G2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion. *J. Exp. Med.*, 175:597-607, 1992.
*		Thorne PS., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. *Am J Ind Med* 25(1):109-12, 1994.
*		Tokunaga T et al., Synthetic Oligonucleotides with Particular Base Sequences form the cDNA Encoding Proteins of *Myobacterium bovis* BCG Induce Interferons and Activate Natural Killer Cells, *Microbiol. Immunol.*, Vol. 36, 1:55-66, 1992.
*		Tokunaga et al., A Synthetic Single-Stranded DNA, Ply (dG, dC), Induces Interferon α/β and -γ, Augments Natural Killer Activity and Suppresses Tumor Growth. *Jpn. J. Cancer Res.*, 79:682-686, June 1988.
C19		**Topalian, S., et al., "Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials", *J of Immunological Methods*, 102:127-141, (1987)**
C20		**Torpey III, D., et al., "Effects of Adoptive Immunotherapy with Autologous CD8+ t Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity, *Clinical Immunology and Immunopathology*, 68:3:263-272, (1993)**
*		Uhlmann et al., Antisense Oligonucleotides: A New Therapeutic Principle. *Chemical Reviews*, 90:543-584, 1990.

9/27/00

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. C1039/7021	SERIAL NO 09/337,619
	APPLICANT: Krieg	
	FILING DATE: June 21, 1999	GROUP 1617

C21	✓	**Vogels, M., et al., "Use of Immune Modulators in nonspecific Therapy of Bacterial Infections", *Antimicrobial Agents and Chemotherapy*, 36:1:1-5, (1992)**
*	✓	Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. *Nature*, 372:L333-335, 1994.
*	✓	Wallace et al., Oligonucleotide probes for the screening of recombinant DNA libraries. *Methods in Enzymology*, 152:432-442 (1987).
*	✓	Weiss R., Upping the Antisense Ante: Scientists bet on profits from reverse genetics. *Science*, 139:108-109, 1991.
*	✓	Whalen R, DNA Vaccines for Emerging Infection Diseases: What If?, *Emerging Infectious Disease*, Vol. 2, 3:168-175, 1996.
C22	✓	**Wooldridge, J., et al., "Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymhoma", *Blood*, 89:8:2994-2998, (1997)**
*	✓	Wu GY et al., Receptor-mediated gene delivery and expression in vivo. *J. Biol. Chem.*, 263:14621-14624, 1988.
*	✓	Wu-Pong S., Oligonucleotides: Opportunities for Drug Therapy and Research. *Pharmaceutical Technology*, 18:102-114, 1994.
*		~~Yamamoto S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. *Microbiol Immunol* 36(9):983-97, 1992.~~
*	✓	Yamamoto S et al., *In vitro* augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from *Mycobacterium bovis* BCG. *Jpn J Cancer Res* 79:866-73, Jul 1988.
*	✓	Yamamoto S., Mode of Action of Oligonucleotide Fraction Extracted from Mycobacterium bovis BCG, *Kekkaku*, Vol. 69, 9:29-32, 1994.
*	✓	Yamamoto S et al., Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity. *J. Immunol.*, Vol. 148, 12:4072-4076, June 15, 1992.
*	✓	Yamamoto T et al., Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length. *Antisense Res. and Devel.*, 4:119-123, 1994.
*	✓	Yamamoto et al., Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity. *Microbiol. Immunol.*, Vol. 38, 10:831-836, 1994.
*	✓	Yamamoto T et al., Synthetic Oligonucleotides with Certain Palindromes Stimulate Interferon Production of Human Peripheral Blood Lymphocytes *in vitro*. *Jpn. J. Cancer Res.*, 85:775-779, 1994.
*	✓	Yi, Ae-Kyung et al., IFN-γ Promotes IL-6 and IgM Secretion in Response to CpG Motifs in Bacterial DNA and Oligonucleotides, *The Journal of Immunology*, pp. 558-564 (1996).
*	✓	Yi, Ae-Kyung et al., Rapid Immune Activation by CpG Motifs in Bacterial DNA, *The Journal of Immunology*, pp. 5394-5402 (1996).
*	✓	Zhao Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. *Blood* 84(11):3660-6, 1 Dec 1994.
*	✓	Zhao Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. *Antisense Res Dev* 3(1):53-66, Spring 1993.
C23	✓	**Hamblin, T., et al., "Ex Vivo Acitivation and Retransfusion of White Blood Cells", *Curr Stud Hematol Blood Transf.*, 57:249-266, (1990)**
C24	✓	**Shimada, S., et al., "Antitumor Acitivity of the DNA Fraction from Mycobacterium bovis BCG. II> Effects on Various Syngeneic Mouse Tumors", *JNCI*, 74:3:681-688, (1985)**

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 08/738,652, filed October 30, 1996, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

9/27/00

09/337,619

EXAMINER	DATE CONSIDERED
	9/27/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.